The authors conducted a placebo-controlled, single-blind, dose-monitored, cross-over study design in 18 healthy volunteers. After 2 weeks of daily oral silver nanoparticle ingestion, platelet activation was not detectable at peak serum silver concentrations <10ug/L.

The goal of this study was to investigate whether an orally ingested commercially available colloidal silver nanoproduct produces pharmacokinetic interference on select cytochrome P450 enzymes.

ASAP Solutions at both 10 and 22 ppm concentrations have no demonstrated anti-probiotic activity, leaving the body’s natural host defense mechanism intact.

Commercial 10-32 ppm nanoscale silver particle solutions studies were retrospectively reviewed in a single blind, controlled, cross-over with intent-to-treat design. Healthy subjects underwent before and after toxicity testing. No morphological changes or pro-inflammatory cytokine generation were detected.